Boxer Capital

Founded 2005

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 54
Average round size
info
The average size of a deal this fund participated in
$88M
Portfolio companies 45
Rounds per year 3.38
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 30
Key employees 3

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Life Science
  • Medical
Summary

The leading representative office of defined VC is situated in the Windermere. The company was established in North America in United States.

The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight AveXis, Passage Bio, Codiak Biosciences. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Medical, Therapeutics. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

Comparing to the other companies, this Boxer Capital performs on 21 percentage points more the average number of lead investments. The increased amount of exits for fund were in 2019. The fund is constantly included in 2-6 deals per year. The important activity for fund was in 2019. Deals in the range of 50 - 100 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Boxer Capital, startups are often financed by OrbiMed, Vivo Capital, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Alexandria Venture Investments, Vivo Capital. In the next rounds fund is usually obtained by RA Capital Management, Tavistock Life Sciences, Surveyor Capital.

We also calculated 3 valuable employees in our database.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Asher Bio

Biotechnology
Therapeutics
$108M01 Sep 2021 San Francisco, California, United States

Point Biopharma

Biopharma
Biotechnology
Therapeutics
$165M01 Jul 2021 Indianapolis, Indiana, United States

Ajax Therapeutics

Biotechnology
Life Science
Medical
$40M01 Jun 2021 Cambridge, Massachusetts, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$82M13 May 2021 Cambridge, Massachusetts, United States

Biotechnology
Health Care
Life Science
Therapeutics
$105M28 Apr 2021 San Diego, California, United States

Biotechnology
Health Care
Information Technology
Pharmaceutical
Travel
$100M13 Apr 2021 New York, New York, United States

Tyra Biosciences

Biotechnology
Life Science
Therapeutics
$106M31 Mar 2021 Carlsbad, California, United States

Centessa Pharmaceuticals

Biotechnology
Pharmaceutical
$250M16 Feb 2021 Cambridge, Massachusetts, United States

Day One Biopharmaceuticals

Biopharma
Biotechnology
Health Care
Pharmaceutical
$130M10 Feb 2021 South San Francisco, California, United States
News
Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Ajax Therapeutics Raises $40 Million Financing To Develop Novel Small Molecules Targeting Cytokine Signaling Pathways for Hematologic Malignancies

– Ajax Therapeutics, Inc. announced the completion of a $40m financing.
– The round was led by EcoR1 Capital LLC with participation from additional new investor, Boxer Capital, as well as co-founding investors Inning One Ventures and Schrödinger, Inc.
– Existing research collaboration partners, Memorial Sloan Kettering Cancer Center (MSK) and NYU Langone Health, also participated in the financing.
– Concurrent with the financing, Scott Platshon, Partner of EcoR1 Capital, will join the Ajax Board of Directors.
– Proceeds from the financing will support the advancement of Ajax’ lead drug development programs targeting hematologic malignancies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Boxer Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: